Background: Endothelial cells, monocytes/macrophages, and vascular smooth muscle cells contribute to the establishment and progression of atherosclerotic lesions by expressing growth and inflammatory factors. The aim of the present study was to determine whether heregulin (HRG) is associated with human coronary artery disease. Methods: Twenty-six fresh human coronary artery segments were collected at autopsy. Expression of cysteine-rich 61 (CYR61) and VEGF in response to HRG was studied in the human endothelial cell line EA.hy926, and expression of CYR61 and HRG was evaluated in activated macrophages isolated from peripheral blood of healthy donors. Results: We found that HRG was overexpressed at the protein and mRNA level in all lesions analyzed and gradually increased as the stages of the lesions progressed. Expression of HRG was observed in the intima primarily in macrophages. The same specimens were analyzed for the expression of CYR61, an angiogenetic factor regulated by HRG in breast cancer epithelial cells. CYR61 was expressed in both normal and atheromatic specimens, but its expression was significantly enhanced in macrophages of the intima. Activation of primary human macrophages results in increased expression of both HRG and CYR61. In addition, studies in endothelial cells where no endogenous HRG is present showed that HRG induces expression of CYR61 and secretion of VEGF. Conclusions: HRG may, therefore, play an important role in the development of coronary artery disease and the expansion of the atherosclerotic plaque and may locally regulate the expression of the angiogenetic factor CYR61.

Keywords:
Angiogenesis, Coronary disease, Growth factors, Macrophages
1.
Ross R: Atherosclerosis – an inflammatory disease. N Engl J Med 1999;340:115–126.
2.
Lusis AJ: Atherosclerosis. Nature 2000;407:233–241.
3.
Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801–809.
4.
Alroy I, Yarden Y: The ErbB signalling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997;410:83–86.
5.
Riese DJ, Stern DF: Specificity within the EGF family/ErbB receptor family signalling network. Bioessays 1998;20:41–48.
6.
Lupu R, Colomer R, Kannan B, et al: Characterization of growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses. Proc Natl Acad Sci USA 1992;89:2287–2291.
7.
Bacus SS, Huberman E, Chin D, et al: A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells. Cell Growth Differ 1992;3:401–411.
8.
Guerra-Vladusic FK, Scott G, Weaver V, et al: Constitutive expression of Heregulin induces apoptosis in an erbB-2 overexpressing breast cancer cell line SKBr-3. Int J Oncol 1999;15:883–892.
9.
Tripathy D, Benz CC: Activated oncogenes and putative tumor suppressor genes involved in human breast cancers. Cancer Treat Res 1992;63:15–60.
10.
Mograbi B, Rochet N, Imbert V, et al: Human monocytes express amphiregulin and heregulin growth factors upon activation. Eur Cytokine Netw 1997;8:73–81.
11.
Moussad EE, Brigstock DR: Connective tissue growth factor: what’s in a name? Mol Genet Metab 2000;71:276–292.
12.
Yang PG, Lau FL: Cyr61, product of a growth factor-induced immediate early gene, is associated with the extracellular matrix and the cell surface. Cell Growth Differ 1991;2:351–357.
13.
Lau LF, Lam SC: The CCN of angiogenic regulators: the integrin connection. Exp Cell Res 1999;248:44–57.
14.
Perbal B: NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues. Mol Pathol 2001;54:57–79.
15.
Kireeva ML, Mo F, Yang GP, et al: Cyr61, a product of a growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesion. Mol Cell Biol 1996;16:1326–1334.
16.
Leu SJ, Lam SC, Lau LF: Pro-angiogenic activities of CYR61 (CCN) mediated through integrins ανβ3 and α6β1 in human umbilical vein endothelial cells. J Biol Chem 2002;277:46248–46255.
17.
Schober JM, Chen N, Grzeszkiewicz TM, et al: Identification of integrin αMβ2 as an adhesion receptor on peripheral blood monocytes for Cyr61 (CCN1) and connective tissue growth factor (CCN2): immediate-early gene products expressed in atherosclerotic lesions. Blood 2002;99:4457–4465.
18.
Springer TA: Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301–314.
19.
Hilfiker A, Hilfiker-Kleiner D, Fuchs M, et al: Expression of CYR61, an angiogenic immediate early gene, in atherosclerosis and its regulation by angiotensin II. Circulation 2002;106:254–260.
20.
Edgell CJS, McDonald CC, Graham JB: Permanent cell line expressing factor VIII related antigen established by hybridization. Proc Natl Acad Sci USA 1983;80:3734–3737.
21.
Rieber AJ, Marr HS, Comer MB, et al: Extent of differentiated gene expression in human endothelium-derived EA.hy926. Thromb Haemost 1993;69:476–480.
22.
Stary HC, Chandler AB, Dinsmore RE, et al: A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995;92:1355–1374.
23.
Hakkinen T, Karkola K, Yla-Herttuala S: Macrophages, smooth muscle cells, endothelial cells, and T-cells express CD40 and CD40L in fatty streaks and more advanced human atherosclerotic lesions. Colocalization with epitopes of oxidized low-density lipoprotein, scavenger receptor, and CD16 (Fc gammaRIII). Virchows Arch 2000;437:396–405.
24.
Panutsopulos D, Zafiropoulos A, Krambovitis E, et al: Peripheral monocytes from diabetic patients with coronary artery disease display increased bFGF and VEGF mRNA expression. J Transl Med 2003;1:6.
25.
Tsai MS, Shamon-Taylor LA, Mehmi I, et al: Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene 2003;22:761–768.
26.
Yen L, Benlimame N, Nie ZR, et al: Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. Mol Biol Cell 2002;13:4029–4044.
27.
Kireeva ML, Latinkic BV, KolesnikovaTV, et al: Cyr61 and Fisp12 are both ECM-associated signaling molecules: activities, metabolism, and localization during development. Exp Cell Res 1997;233:63–77.
28.
Latinkic BV, Mo F-E, Greenspan JA, et al: Promoter function of the angiogenic inducer Cyr61 gene in transgenic mice: tissue specificity, inducibility during wound healing, and role of the serum response element. Endocrinology 2001;142:2549–2557.
29.
O’Brien TP, Yang GP, Sanders L, et al: Expression of cyr61, a growth factor-inducible immediate-early gene. Mol Cell Biol 1990;10:3569–3577.
30.
Ryseck RP, Macdonald-Bravo H, Mattei MG, et al: Structure, mapping, and expression of fisp-12, a growth factor-inducible gene encoding a secreted cysteine-rich protein. Cell Growth Differ 1991;2:225–233.
31.
Raines EW, Ross R: Multiple growth factors are associated with lesions of atherosclerosis: specificity or redundancy? Bioessays 1996;18:271–282.
32.
Rutanen J, Leppanen P, Tuomisto TT, et al: Vascular endothelial growth factor-D expression in human atherosclerotic lesions. Cardiovasc Res 2003;59:971–979.
33.
Inoue M, Itoh H, Ueda M, et al: Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 1998;98:2108–2116.
34.
Babic AM, Kireeva ML, Kolesnikova TV, et al: CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci USA 1998;95:6355–6360.
35.
Babic AM, Chen CC, Lau LF: Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin ανβ3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol Cell Biol 1999;19:2958–2966.
36.
Tsai MS, Hornby AE, Lakins J, et al: Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies. Cancer Res 2000;60:5603–5607.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.